Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
Vir Biotechnology’s VIR-5500 tests whether dual-masked T-cell engagers can finally work in metastatic prostate cancer
Vir Biotechnology’s VIR-5500 shows early promise in metastatic prostate cancer. Find out what changes, what remains uncertain, and what comes next.